	Synexus continues to expand across Eastern Europe with three new Dedicated Research Centres in Bulgaria, Poland and Romania, bringing the total to nine centres in Eastern Europe and a total network of 25 across Europe and Africa. These new centres will provide the company’s clients in pharma and CROs with an expanding pool of patients.
	
	The population of Central and Eastern European countries exceeds that of either the US or the five largest Western European markets combined, coupled with its excellent healthcare professionals,  which is the reason it has continued to remain important to the clinical trials market.
	
	Synexus which is based in the UK is the world’s largest multi-national company entirely focused on the recruitment and running of clinical trials at its own 25 dedicated research centres and 24 affiliated sites.
	
	Commenting on the additional centres, Christophe Berthoux, CEO at Synexus, said: “This is our ninth Dedicated Research Centre in Eastern Europe which will help us to provide much greater support to the global pharmaceutical industry. Since we opened our first centre in Poland in 2006 we have had an ongoing programme of investment in the region. Throughout the world we are upgrading our centres to provide the very latest facilities for our patients and to provide our clients in pharma with the most accurate data.”
	
	The new Polish facility is Synexus’ largest research centre in the world. It occupies 1000 m2 at Beniowskiego Street, in Gdansk. Dr Magdalena Przekwas-Jaruchowska, the centre’s Director oversaw the opening ceremony which included representatives from the local authority, the British Embassy, the medical university and from patients’ associations.
	
	Romania’s new 820 m2 centre is based in the capital, Bucharest, which has a population of two million. Romania has been part of Synexus’ development plans since early 2000, as the country’s total population is over 20 million and the number of new clinical trials which has been granted approval during the last five years is at least 200.
	
	A total area of 650 m2 for the Dedicated Research Centre in Bulgaria is situated in Sofia with eight medical rooms, two administration rooms, monitoring and meeting rooms and other areas. This is an innovative project for Bulgaria which aims to offer its patients access to new drugs including the fields of pulmonology, rheumatology, neurology, endochrinology, cardiology, gastroenterology and dermatology.
	
	All Synexus’ 25 clinics across Europe and Africa focus on undertaking clinical trials in the therapy areas where the company can provide most value. Particular attention is devoted to the areas of cardiovascular, metabolic (diabetes and obesity), musculoskeletal, respiratory and central nervous system (dementia and pain) trials.
	
	The new Dedicated Research Centres in Bulgaria, Poland and Romania provide Synexus with a further platform to build on existing success. Both patients and the pharmaceutical industry alike will benefit from the increased ability to develop clinical research capabilities across the region.